CellPro Inc. (CPRO)
Marc Ostro of UBS Securities initiated coverage of CPRO with a "buy" and a 12-month price target of $17. He said that the combination of good yields and purity, ease of use, small size, low cost and speed should make the Bothell, Wash., company's Ceprate SC stem cell separation system